Verticaltalk - Integrated Media Solutions in the B2B Arena

Pharmaceutical Technology - A Key Resource to Pharmaceutical Technology


Section Banner

Press Releases

Archives - 2007

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Archives - 2008

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

November 2008

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

Thursday 20 Nov, 2008

Teva Provides Update on Generic Pulmicort Respules® Launch

Thursday 20 Nov, 2008

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

Wednesday 19 Nov, 2008

IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicin

Tuesday 18 Nov, 2008

Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults

Tuesday 18 Nov, 2008

Daiichi Sankyo and Biota (ASX:BTA) start Phase III trials in Asia for next generation Relenza product

Monday 17 Nov, 2008

Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics

Monday 17 Nov, 2008

FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint

Monday 17 Nov, 2008

ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III) for Treatment of Visual Disorders

Friday 14 Nov, 2008

FDA Approves BANZEL(TM) (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder

Friday 14 Nov, 2008

GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study

Thursday 13 Nov, 2008

Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders

Wednesday 12 Nov, 2008

Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders

Wednesday 12 Nov, 2008

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

Tuesday 11 Nov, 2008

TNFerade(TM) Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer

Tuesday 11 Nov, 2008

Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring

Monday 10 Nov, 2008

Lab21 Expands International Business with Launch into India with a Million Dollar Syphilis Testing Agreement

Monday 10 Nov, 2008

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

Sunday 9 Nov, 2008

Winston Laboratories, Inc. Announces Licensing Agreement with sanofi-aventis Canada Inc. in Canada

Friday 7 Nov, 2008

Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin

Thursday 6 Nov, 2008

Pfizer Discontinues Development Program for Its Phase 3 Obesity Compound (CP-945,598)

Wednesday 5 Nov, 2008

Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets

Wednesday 5 Nov, 2008

FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children

Tuesday 4 Nov, 2008

Cardiovascular Systems Signs Merger Agreement

Tuesday 4 Nov, 2008

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

Monday 3 Nov, 2008

Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

Monday 3 Nov, 2008

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

Monday 3 Nov, 2008